Biography
Dr. Palanisamy obtained a Bachelor of Science degree in Zoology in 1990 and a Master of Science degree in Biochemistry in 1992 from the University of Madras, located in India. In 2001, he successfully obtained a Doctor of Philosophy degree in Biochemistry from the University of Madras. After obtaining his Ph.D., he pursued postdoctoral research at the University of New Hampshire and Colorado State University in 2001-2006. Subsequently, he assumed the position of resident assistant professor at the University of California, Los Angeles. In 2009, Dr. Palanisamy assumed the position of assistant professor at the Medical University of South Carolina. Subsequently, he advanced to the rank of Associate Professor in 2014 and maintained this position until the completion of the year 2023. In September 2023, Dr. Palanisamy assumed the position of Full Professor within the division of Molecular Medicine, Department of Internal Medicine, at the University of New Mexico. Dr. Palanisamy is also a full-time member of the UNM Comprehensive Cancer Center.
Personal Statement
NCBI Bibliography:
https://www.ncbi.nlm.nih.gov/myncbi/viswanathan.palanisamy.1/bibliography/public/
MEMBERSHIP IN SCIENTIFIC SOCIETIES
American Association of Cancer Research - 2009-present
American Association of Dental Research - 2009-present
RNA Society 2012-2019
American Society for Biochemistry and Molecular Biology 2011-present
Areas of Specialty
1. Biochemistry and Molecular Biology
2. Head and Neck cancer research
Achievements & Awards
Awards, Honors, Membership in Honorary Societies
1. MUSC Foundation Developing Scholar Award 2013
2. Outstanding graduate thesis award, (2001) University of Madras 2001
Senior Research Fellowship by the Council of Scientific and Industrial Research, Govt of India.
3. Outstanding Student Undergraduate Award, Madurai Kamaraj University, India, 1990.
Gender
Male
Languages
- Tamil
- English
Courses Taught
Teaching Experience
2021-2023 Medical Biochemistry for MD students MMT 2015-2018: Instructor, Dental Biochemistry, OHS-601 2015-2017: Instructor, Nutritional Biochemistry, OHS-807 2013-2017: Instructor, Biochemical aspects of Oral Biology OHS-902 2012-2015: Director and Instructor, Dental Biochemistry, OHS-601 2009-2015: Special lecturing on Saliva Diagnostics for Dental Students and Summer Students
Research and Scholarship
1. Majumder M, Chakraborty P, Mohan S, Mehrotra S, Palanisamy V. HuR as a molecular target for cancer therapeutics and immune-related disorders. Adv Drug Deliv Rev. 2022 Sep;188:114442. doi: 10.1016/j.addr.2022.114442. Epub 2022 Jul 8. Review. PubMed PMID: 35817212.
2. Majumder M, Palanisamy V. RNA binding protein FXR1-miR301a-3p axis contributes to p21WAF1 degradation in oral cancer. PLoS Genet. 2020 Jan;16(1):e1008580. doi: 10.1371/journal.pgen.1008580. eCollection 2020 Jan. PubMed PMID: 31940341; PubMed Central PMCID: PMC6986764.
3. McClure JJ, Palanisamy V. Muscle-Specific FXR1 Isoforms in Squamous Cell Cancer. Trends Cancer. 2019 Feb;5(2):82-84. doi: 10.1016/j.trecan.2018.12.001. Epub 2018 Dec 21. Review. PubMed PMID: 30755307; PubMed Central PMCID: PMC6404231.
4. Talwar S, Balasubramanian S, Sundaramurthy S, House R, Wilusz CJ, Kuppuswamy D, D'Silva N, Gillespie MB, Hill EG, Palanisamy V. Overexpression of RNA-binding protein CELF1 prevents apoptosis and destabilizes pro-apoptotic mRNAs in oral cancer cells. RNA Biol. 2013 Feb;10(2):277-86. doi: 10.4161/rna.23315. Epub 2013 Jan 16. PubMed PMID: 23324604; PubMed Central PMCID: PMC3594286.
5. Majumder M, Palanisamy V. RNA binding protein FXR1-miR301a-3p axis contributes to p21WAF1 degradation in oral cancer. PLoS Genet. 2020 Jan;16(1):e1008580. doi: 10.1371/journal.pgen.1008580. eCollection 2020 Jan. PubMed PMID: 31940341; PubMed Central PMCID: PMC6986764.